S&P picks: Why the biotech sector looks healthy
Steven Silver, S&P's biotechnology equity analyst, thinks the industry is positioned for renewed investor interest in 2010.
Learn more about reprints and licensing for this article.
Learn more about reprints and licensing for this article.
In the third installment of the InvestmentNews four-part Lifestage series, we focus on those 60 to 75 — people on the verge of retiring and those who are in the first stage of retirement.
Standard & Poor's Equity Research recently upgraded its outlook for the biotechnology industry to positive from neutral.
Steven Silver, S&P's biotechnology equity analyst, thinks the industry is positioned for renewed investor interest in 2010.
